Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer

Lung Cancer

Volumn 85, Issue 3, 2014, Pages 420-428

  Langer, Corey J ^a   Albert, Istvan ^b   Ross, Helen J ^c   Kovacs, Peter ^d   Blakely, L Johnetta ^e   Pajkos, Gabor ^f   Somfay, Attila ^g   Zatloukal, Petr ^h   Kazarnowicz, Andrzej ⁱ   Moezi, Mehdi M ^j   Schreeder, Marshall T ^k   Schnyder, Judy ^l   Ao Baslock, Ada ^m   Pathak, Ashutosh K ⁿ   Berger, Mark S ^l  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Pulmonológiai Rehabilitációs Osztály   (Hungary)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e WEST CLINIC   (United States)

^f BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

^g UNIVERSITY OF SZEGED   (Hungary)

^h UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

ⁱ Independent Public Center of Tuberculosis and Lung Diseases   (Poland)

^j Cancer Specialists of North Florida   (United States)

^k Clearview Cancer Institute   (United States)

^l Gemin X Pharmaceuticals   (United States)

^m Powered 4 Significance LLC   (United States)

ⁿ TEVA PHARMACEUTICALS   (Israel)

more..

Author keywords

Bcl 2; Carboplatin; Etoposide; Obatoclax; Randomized; SCLC

Indexed keywords

CARBOPLATIN; ETOPOSIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; OBATOCLAX; ANTINEOPLASTIC AGENT; PYRROLE DERIVATIVE;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BACKACHE; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONFUSION; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYTOKINE RELEASE SYNDROME; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG INFUSION; DYSPEPSIA; DYSPNEA; EUPHORIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SMALL CELL LUNG CANCER; SOMNOLENCE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; VOMITING; AGED; CLINICAL TRIAL; COMORBIDITY; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMORBIDITY; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PYRROLES; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84926408201     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.05.003     Document Type: Article

References (31)

1. American Cancer Institute. Cancer Facts & Figures 2012. 2012. Available at: . Accessed December 4, 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
2. Siegel R., Naishadham D., Jemal A. Cancer Statistics, 2013. CA: A Cancer Journal for Clinicians 2013, 63:11-30.
3. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539-4544.
4. Demedts I.K., Vermaelen K.Y., van Meerbeeck J.P. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010, 35:202-215.
5. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology. Small cell lung cancer. Version 1.2014 2013, Available at:, . Accessed December 4, 2013. http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.
6. National Institute for Health Clinical Excellence NICE Clinical Guideline 121. Lung cancer. The diagnosis and treatment of lung cancer 2011, Available at:, . Accessed December 4, 2013. http://www.nice.org.uk/nicemedia/live/13465/54202/54202.pdf.
7. Sorensen M., Pijls-Johannesma M., Felip E. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v120-v125.
8. Rudin C.M., Salgia R., Wang X., Hodgson L.D., Masters G.A., Green M., et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008, 26:870-876.
9. Socinski M.A., Smit E.F., Lorigan P., Konduri K., Reck M., Szczesna A., et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009, 27:4787-4792.
10. Socinski M.A., Weissman C., Hart L.L., Beck J.T., Choksi J.K., Hanson J.P., et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 2006, 24:4840-4847.
11. Chipuk J.E., Moldoveanu T., Llambi F., Parsons M.J., Green D.R. The BCL-2 family reunion. Mol Cell 2010, 37:299-310.
12. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002, 2:647-656.
13. Fokkema E., De Vries E.G., Groen H.J., Meijer C., Timens W. Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment. Virchows Arch 2003, 442:349-355.
14. Jiang S.X., Sato Y., Kuwao S., Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1995, 177:135-138.
15. Sartorius U.A., Krammer P.H. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002, 97:584-592.
16. Takayama K., Ogata K., Nakanishi Y., Yatsunami J., Kawasaki M., Hara N. Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer. Cancer J Sci Am 1996, 2:212-216.
17. Yan J.J., Chen F.F., Tsai Y.C., Jin Y.T. Immunohistochemical detection of Bcl-2 protein in small cell carcinomas. Oncology 1996, 53:6-11.
18. Paik P.K., Rudin C.M., Brown A., Rizvi N.A., Takebe N., Travis W., et al. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 2010, 66:1079-1085.
19. Chiappori A., Schreeder M.T., Moezi M.M., Stephenson J., Blakely J.L., Salgia R., et al. A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC). J Clin Oncol 2009, 27:3576.
20. Chiappori A.A., Schreeder M.T., Moezi M.M., Stephenson J.J., Blakely J., Salgia R., et al. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer 2012, 106:839-845.
21. Baka S., Califano R., Ferraldeschi R., Aschroft L., Thatcher N., Taylor P., et al. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 2008, 99:442-447.
22. Niell H.B., Herndon J.E., Miller A.A., Watson D.M., Sandler A.B., Kelly K., et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005, 23:3752-3759.
23. Pandya K.J., Dahlberg S., Hidalgo M., Cohen R.B., Lee M.W., Schiller J.H., et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007, 2:1036-1041.
24. Spigel D.R., Townley P.M., Waterhouse D.M., Fang L., Adiguzel I., Huang J.E., et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011, 29:2215-2222.
25. Ready N., Karaseva N.A., Orlov S.V., Luft A.V., Popovych O., Holmlund J.T., et al. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol 2011, 6:781-785.
26. Heist R.S., Fain J., Chinnasami B., Khan W., Molina J.R., Sequist L.V., et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 2010, 5:1637-1643.
27. Baggstrom M.Q., Qi Y., Koczywas M., Argiris A., Johnson E.A., Millward M.J., et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol 2011, 6:1757-1760.
28. Rudin C.M., Hann C.L., Garon E.B., Ribeiro de Oliveira M., Bonomi P.D., Camidge D.R., et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012, 18:3163-3169.
29. Chiappori A., Williams C., Northfelt D.W., Adams J.W., Malik S., Edelman M.J., et al. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. J Thorac Oncol 2014, 9:121-125.
30. Micha D., Cummings J., Shoemaker A., Elmore S., Foster K., Greaves M., et al. Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer. Clin Cancer Res 2008, 14:7304-7310.
31. Dean E.J., Cummings J., Roulston A., Berger M., Ranson M., Blackhall F., et al. Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Neoplasia 2011, 13:339-347.